Herein, we present our institutional experience of 51 patients with DLBCL who underwent bRT prior to CD19-directed CAR T-cell therapy, analyzing patterns of failure and examining the patient and treatment factors associated with the most benefit from bRT. This evidence concerns the gene CD19 and diffuse large B-cell lymphoma.